<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03761537</url>
  </required_header>
  <id_info>
    <org_study_id>LP0162-1346</org_study_id>
    <nct_id>NCT03761537</nct_id>
  </id_info>
  <brief_title>Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Have Contraindications to Oral Cyclosporine A</brief_title>
  <acronym>ECZTRA 7</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre, Phase 3 Trial Investigating the Efficacy, Safety, and Tolerability of Tralokinumab Administered in Combination With Topical Corticosteroids to Adult Subjects With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Have Contraindications to Oral Cyclosporine A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      To demonstrate that tralokinumab in combination with TCS is superior to placebo in
      combination with topical corticosteroids (TCS) in treating severe AD in subjects who are not
      adequately controlled with or have contraindications to oral cyclosporine A (CSA).

      Secondary objectives:

      To evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of
      AD, itch, and health-related quality of life compared to placebo in combination with TCS.

      To evaluate the safety of tralokinumab in combination with TCS when treating severe AD in
      subjects who are not adequately controlled with or have contraindications to oral CSA
      compared to placebo in combination with TCS.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 28, 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>At least 75 reduction in EASI score (EASI75)</measure>
    <time_frame>Week 16</time_frame>
    <description>EASI (Eczema Area and Severity Index) is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IGA score of 0 (clear) or 1 (almost clear)</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>IGA (Investigator's Global Assessment) is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA score of 0 (clear) or 1 (almost clear)</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <description>IGA (Investigator's Global Assessment) is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SCORAD</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>SCORAD (Scoring Atopic Dermatitis) is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SCORAD</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <description>SCORAD (Scoring Atopic Dermatitis) is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EASI75 response</measure>
    <time_frame>Week 26</time_frame>
    <description>EASI (Eczema Area and Severity Index) is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Worst Daily Pruritus NRS (weekly average) of at least 4</measure>
    <time_frame>Week 16</time_frame>
    <description>NRS (Numeric Summary Score). Subjects will assess their worst itch severity over the past 24 hours using an 11-point numeric rating scale ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Worst Daily Pruritus NRS (weekly average) of at least 4</measure>
    <time_frame>Week 26</time_frame>
    <description>NRS (Numeric Summary Score). Subjects will assess their worst itch severity over the past 24 hours using an 11-point numeric rating scale ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DLQI score</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>DLQI (Dermatology Life Quality Index) is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their health-related quality of life (HRQoL) over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4-point Likert scale (0 = not at all ∕not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor HRQoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DLQI score</measure>
    <time_frame>Week 0 to Week 26</time_frame>
    <description>DLQI (Dermatology Life Quality Index) is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their health-related quality of life (HRQoL) over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4-point Likert scale (0 = not at all ∕not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor HRQoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Week 0 to Week 40</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-drug antibodies</measure>
    <time_frame>Week 0 to Week 40</time_frame>
    <description>yes/no</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">333</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Tralokinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tralokinumab loading SC injection on Day 0 followed by multiple tralokinumab injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo loading SC injection on Day 0 followed by multiple placebo injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tralokinumab</intervention_name>
    <description>Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.</description>
    <arm_group_label>Tralokinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo contains the same excipients in the same concentration only lacking tralokinumab.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Age 18 and above

          -  Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD

          -  History of AD for 1 year or more

          -  Subjects with a history within 1 year prior to screening of inadequate response to
             treatment with topical medications or subjects for whom topical treatments are
             otherwise medically inadvisable

          -  AD involvement of 10% (or more) body surface area at screening and baseline (visit 3)
             according to component A of SCORAD

          -  Documented history of either no previous CSA exposure and not currently a candidate
             for CSA treatment OR previous exposure to CSA in which case CSA treatment should not
             be continued or restarted

          -  Subjects must have applied a stable dose of emollient twice daily (or more, as needed)
             for at least 14 days before randomisation

        Key Exclusion Criteria:

          -  Subjects for whom TCSs are medically inadvisable in the opinion of the investigator

          -  Use of tanning beds or phototherapy (NBUVB, UVB, UVA1, PUVA), within 6 weeks prior to
             randomisation

          -  Treatment with immunomodulatory medications or bleach baths within 4 weeks prior to
             randomisation

          -  Treatment with topical phosphodiesterase-4 (PDE-4) inhibitor within 2 weeks prior to
             randomisation

          -  Receipt of any marketed or investigational biologic agent (e.g. cell-depleting agents
             or dupilumab) within 6 months prior to randomisation or until cell counts return to
             normal, whichever is longer

          -  History of any active skin infection within 1 week prior to randomisation

          -  History of a clinically significant infection (systemic infection or serious skin
             infection requiring parenteral treatment) within 4 weeks prior to randomisation

          -  A helminth parasitic infection within 6 months prior to the date informed consent is
             obtained that has not been treated with, or has failed to respond to, standard of care
             therapy

          -  Tuberculosis requiring treatment within the 12 months prior to screening. Evaluation
             will be according to local guidelines as per local standard of care

          -  History of any known primary immunodeficiency disorder including a positive HIV test
             at screening, or the subject taking antiretroviral medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Herstal</city>
        <zip>B-4040</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Loverval</city>
        <zip>6280</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Maldegem</city>
        <zip>9990</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Karlovy Vary</city>
        <zip>36000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Kutna Hora</city>
        <zip>284 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Prague 5</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Prague 8</city>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Prague</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Prague</city>
        <zip>11000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Bad Bentheim</city>
        <zip>48455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117,</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Dülmen</city>
        <zip>48249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Halle</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Hanover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Mainz</city>
        <zip>55128</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Osnabrück</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Selters</city>
        <zip>56242</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-375</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Bochnia</city>
        <zip>32-700</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Kraków</city>
        <zip>30-149</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-209</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-530</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-369</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-312</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-817</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-625</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-758</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Wrocław</city>
        <zip>50-001</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Łódź</city>
        <zip>90-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Łódź</city>
        <zip>90-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Madrid</city>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD5 0NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Cottingham</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Kirkcaldy</city>
        <zip>KY2 5AH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>London</city>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigationel Site</name>
      <address>
        <city>Wakefield</city>
        <zip>WF1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

